Wednesday, May 06, 2015 3:23:57 AM
Radient Restructured By A Planned Reverse Merger
We will show how the Lenders converted and accumulated their limitation of 25 per cent of the RXPC outstanding shares along with the Provista/GCDX Angel investors 65 per cent of the outstanding and the 10 per cent of a few longs. Radient placed 4,509,000,000 shares into the float and the 491 million are for the Attorney firm that will be able to convert $300,000 of debt for around a holding of 34 million shares. The remaining shares will be for Mac, Akio,etc..The 1.8 million dollars of share based funds...Mac and Akio aren't going anywhere. Tomorrow we will break down the 25 per cent owned by the 2011 lenders 9.99 per cent,collectively, John Fife and St. George, 10 per cent, Capital Inventures 4.99 per cent. etc... Stay tuned
Gold Seeker Stated:
"Radient was insolvent in December 2012."
"That is when they disclosed that they owed $900,000 for operational costs (vendors, suppliers, leases) and had no way to pay. That is the definition of "insolvent."
Even if UNI still paid Radient the $200,000 per year royalty fee after the last patent expired, it would not have saved Radient from death.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113268667
Gold, You stated that Radient was insolvent in December 2012. When we saw that post, we knew that it couldn't be true..We did give you the benefit of the doubt and did some research. We checked all the 8-K's for the year 2012 and could not find the disclosure you stated or any language about "Radient being insolvent. We thought maybe you were referring to 2011 as well, but did not find it there, as well.
Here is what we found in 2012..
From an operational perspective, we continue to sell and ship Onko-Sure test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, the Company continues to maintain its operations in Tustin, relying on selective former employees that continue to work as consultants to the Company. We are also engaged in business discussions with other companies seeking to license Onko-Sure for various international territories. These licensing agreements, if completed, are anticipated to provide the Company with the funds necessary to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. There can be no guarantee that any new licensing transactions will be completed.
As of October 3, 2012, we had 3,235,210,154 shares of common stock issued and outstanding.
http://www.sec.gov/Archives/edgar/data/838879/000114420412054967/v325211_8ka.htm
http://www.sec.gov/cgi-bin/browse-edgar?company=Radient+Pharmaceuticals&owner=exclude&action=getcompany
This is the first 8-K in 2013 and the company is still selling Onko-Sure in territories specified within the 8-K..Still no mention of insolvency.
From an operational perspective, with appropriate capital, we can continue to sell and ship Onko-Sure® test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, we continue to maintain our offices and FDA approved manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. We are also engaged in business discussions with other companies seeking to license or purchase Onko-Sure for various domestic and international territories, although we have not entered into any formal agreements at this time. We are hopeful that if we can complete a sufficient number of these licensing and sales agreements, we will have enough capital to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. These agreements may also allow us to restructure or convert to equity our existing notes payable in order to significantly reduce or eliminate a majority of the liabilities on our balance sheet. There can be no guarantee that any new licensing, purchase or restructuring transactions will be completed or that they will provide sufficient capital to carry out our plans.
As of June 10th 2013, we had approximately 4,508,746,417 shares of common stock issued and outstanding.
http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113_radientpharm.htm
This is the only SEC filing we found stating that radient was insolvent. This is from May 6, 2013. Radient was NOT insolvent in December 2012 as you claim. We knew this wasn't true because Radient entered into an agreement with Global Cancer Diagnostics in October 2012 and was receiving licensing fees and royalty fees. In June 2013 AMDL Diagnostics a wholly owned subsidiary entered into an agreement with Uni-Pharma and received royalties as you stated in your post, except it was $100,000 and not $200,000 as you stated. The monies from Uni-Pharma were being collected by AMDL Diagnostics Inc. and were used to pay down the Radient debt. The monies from the India Government program and SRL Diagnostics and Metropolis are also being collected by AMDL.
Despite significant financial hardship, the Company continues to maintain its offices and manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. The Company is currently insolvent and the new Board of Directors and the new senior management of the Company have been appointed to attempt to restructure the Company. There can be no guarantee that any new business or restructuring transactions will be completed or that they will provide sufficient capital to carry out the Company's business.
On April 15, 2014, the Company executed an Offer of Settlement with the Securities and Exchange Commission (“Commission”) pursuant to Section 12(j) of the Securities Exchange Act of 1934, revoking the registration of the Company’s securities.
http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm
Gold Seeker also Stated:
"Radient revoked share registration to hide revenues?"
Instead of filing financials, Radient revoked share registration, because filing financials would reveal revenues that Radient wants to hide?
Radient said "we are insolvent" in an SEC filing when in truth they were making $$$ millions selling onko-sure in India?
If true, RXPC shareholders think this is good?"
Fascinating.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113368735
Gold, What we referring to is that Radient didn't file their 2012, 2013 and 2014 annual reports up to March 1, 2014.Radient became insolvent on March 1, 2014 when it became a Void Delaware Corporation.AMDL Diagnostics Inc has all the assets in their corporation along with the agreements. They are also paying down the debt. The Radient Corporation is insolvent but AMDL Diagnostics Inc. is still operation as the company has stated in their PR;s and SEC Filings since 2009 when the Corporation was formed.. The President of AMDL Diagnostics Inc. is Mac and the Secretary is Akio..They are also the officers of Radient. According to the May 6, 2013 8-K they did not resign as officers of radient. Mac is still the President and Akio is the Secretary..Here is the proof..SEC Filings are Facts you understand..Also you mentioned in a post that Mac couldn't be found.Mac is not hiding, he can be found in the AMDL Dianostics and the Radient Corporation as the President of both Corporations.
On April 30, 2014, the Board of Directors of the Company including Mr. Douglas C. MacLellan and Mr. Michael Christiansen appointed the following persons to the Company's Board: Mr. Jim Green, Mr. Darren Brown, Mr. Bill White and Mr. Dennis Charter. Additionally, the following persons will be appointed to the following positions:
Immediately following these appointments, Mr. MacLellan resigned as Chairman and CEO and Mr. Christiansen resigned as the Company's only other board member. Separately, Mr. Akio Ariura the Company's previous CFO and COO, resigned from both positions on April 28, 2014. None of these directors or officers resigned as a result of a disagreement with the Company.
http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm
Here is the SEC 8-K showing Mac as President and Akio as Secretary..Interesting they performed a Power of attorney in case one passed away..It was done on July 9, 2012 Four days prior to the Global Cancer Diagnostics agreement..
Signature Title Date
/s/ Douglas C. MacLellan President, Chief Executive Officer, and Director June 29, 2012
DOUGLAS C. MACLELLAN (Principal Executive Officer)
/s/ Akio Ariura Chief Operating Officer, Chief Financial Officer June 29, 2012
AKIO ARIURA and Secretary (Principal Financial Officer and Principal Accounting Officer)
/s/ Michael Boswell Director June 29, 2012
MICHAEL BOSWELL
Filing Date
2012-07-09
http://www.sec.gov/Archives/edgar/data/838879/000114420412038691/0001144204-12-038691-index.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420412037457/v317455_10ka.htm
The Power of attorney was signed on June 29, 2012 and posted on July 9, 2012..This is when Global Cancer Diagnostics and provista Diagnostics and the Angel Investors began their Creeping takeover of 65 per cent of the RXPC shares. Check out the volume the day before the Power of Attorney was signed and the day after the 10-K was filed. The Agreement between Radient and GCDX wasn't signed until July 13, 2012 and the 8-K was released on July 17, 2012... No retail or what you call"ebabies" even touched the stock.. This is because their weren't no "ebabies" buying the stock over the 2 year period, only Provista Angel Investors, Lenders converting, and a few investors including Dc and Guardianagel
Jul 18, 2012 0.00 0.00 0.00 0.00 28,268,400 0.00
Jul 17, 2012 0.00 0.00 0.00 0.00 22,938,000 0.00
Jul 16, 2012 0.00 0.00 0.00 0.00 36,264,300 0.00..
Jul 13, 2012 0.00 0.00 0.00 0.00 25,656,000 0.00
Jul 12, 2012 0.00 0.00 0.00 0.00 32,886,000 0.00
Jul 11, 2012 0.00 0.00 0.00 0.00 94,461,400 0.00
Jul 10, 2012 0.00 0.00 0.00 0.00 524,879,000 0.00
Jul 9, 2012 0.00 0.00 0.00 0.00 30,715,900 0.00
Jul 6, 2012 0.00 0.00 0.00 0.00 8,430,000 0.00
Jul 5, 2012 0.00 0.00 0.00 0.00 18,487,000 0.00
Jul 4, 2012 0.00 0.00 0.00 0.00 0 0.00
Jul 3, 2012 0.00 0.00 0.00 0.00 23,972,900 0.00
Jul 2, 2012 0.00 0.00 0.00 0.00 166,400,100 0.00
Jun 29, 2012 0.00 0.00 0.00 0.00 64,732,200 0.00
Jun 28, 2012 0.00 0.00 0.00 0.00 182,674,700 0.00
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
Mac and Akio will have the power to re-instate Radient Pharmaceuticals..Here is the Delaware Corporation Law.
may at any time procure an extension, restoration, renewal or revival of its charter, together with all the rights, franchises, privileges and immunities and subject to all of its duties, debts, and liabilities which had been secured or imposed by its original charter and all amendments thereto by filing with the Secretary of State a certificate of its last acting president and secretary or treasurer, or other officers to be elected as hereinafter provided, duly sworn or affirmed to by such officers before any person authorized by the laws of this State to administer oaths or affirmations, which certificate shall set forth:
If the last president and secretary or treasurer or the officers performing the functions of said offices or any of them of any such corporation so desiring to renew or revive its charter should be dead at the time of such renewal or should refuse or neglect to act with respect thereto as provided in the first paragraph of this section, the directors of such corporation or the survivors of them,....
http://delcode.delaware.gov/sessionlaws/ga105/chp147.shtml
Here is the breakdown of the Lender conversions and the Provista/GCDX Angel investors and a few longs.
*The Lenders started converting..6 Trading days totaling 1.226 Billion shares of volume.
May 24, 2012-June 1, 2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528
(Lender conversions along with Angel investors...5 Trading days and 584 Million shares of volume.
June 13, 2012-June 25, 2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528
*Lender conversions and Angel Investors..619 million shares of volume in 2 trading days.
June 28,2012-July 2,2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
*Lender conversions and Angel investors..1.2 Billion shares of volume in 4 trading days.
September 20, 2012-October 1, 2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
The 2012 conversions and accumulation volume totaled 4 billion in 20 trading days. That is an accumulation of 2 Billion shares being held by Lenders, Angel investors, and a few long investors.
*Lenders conversions and Angel investors.
1.3 billion volume in 6 trading days.
February 1, 2013-March 28, 2013
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=330
*Lender conversions and angel investors.
622 million of volume in 3 days of trading.
April 4, 2013-April 26, 2013
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=264
*Lender conversions and angel investors.
760 million shares of volume in 4 trading days.
July 3, 2013-July 9, 2013
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=198
Total volume in 2013 was 2.7 billion shares in 13 trading days. 1.35 billion shares accumulated.
*Angel investors.
780 million in volume in 2 trading days.
February 24, 2014-February 25, 2014
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=66
*Angel investors.
756 million shares of volume in 4 trading days.
March 20,2014-March 27,2014
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=66
*Angel investors
745 million shares of volume in 2 days of trading.
May 6, 2014-May 7,2014
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=0
2014 total volume 2.28 billion shares in 2 trading days. accumulation and holding 1.14 billion shares.
Total 2012,2013,and 2014...9 billion total volume in 35 trading days and 4.5 billion shares held by Lenders, Angel investors, and Longs...The lenders holding 25 per cent, angel investors 65 per cent and the longs 10 percent...During the time of the accumulation, the lenders converted shares up to their limitations. Then when Radient released more shares into the float, the lenders would purchase shares.. This was done a number of times..We have saved our emails from the transfer agent with the outstanding share count and when they were released...4.5 billion shares accumulated in 35 days.
DCSPKA You said:
SRL Diagnostics India and AMDL Australia connection will be heating up now that AMDL Australia has chosen not to renew its corporate status. Lets see exactly what effect it will have on Radient/AMDL Diagnostics.
I am especially interested on the synergy between AMDL Australia & AMDL Diagnostics.
AMDL Diagnostics- come out, come out, where ever you are?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111001885
Here's Jonny...Look who is checking out Jonny...
Jonny Deez
Orange County, California Area
https://www.linkedin.com/pub/jonny-deez/75/469/933?trk=pub-pbmap
Srinivas Yadav
it at AMDL Australia
Kurnool, Andhra Pradesh, India Medical Devices
https://www.linkedin.com/pub/srinivas-yadav/53/417/230?trk=pub-pbmap
Ikrar Khan
CSE at AMDL Australia
Noida Area, India Medical Devices
https://www.linkedin.com/pub/ikrar-khan/36/632/5a4?trk=pub-pbmap
Aussie with no mention of Radient..Go figure...Just a temp..lol
Darren Brown
Director at Cancer Screen Technologies Ltd
Melbourne Area, Australia
Management Consulting
Current
OnlineCapital Consulting, Cancer Screen Technologies Ltd
Previous
AMDL Australia, Hudson & Young, eWealthBuild Consulting
https://au.linkedin.com/in/dbrown197
***************************************************************
We have added these links to the SRL and Metropolis section of web sites. As you can see the two largest Diagnostics companies in India are selling Onko-Sure..SRL Limited and Metropolis Healthcare., Our sources told us that Metropolis is using the brand name Cancer 8 because SRL is using Onko-Sure.The 10 Million dollar deal with the India Government that was delayed in 2011 has apparently come to fruition. Radient had not filed their 2012,2013,2014 for a reason. To act like a private company without having to show the revenues from the India deal. The Indian deal consummated in 2013. On February 1, 2013, SRL sent out the first hint of the 10 million deal. Some will call this "India hype" or marijuana hype, whatever name was convenient at the time to falsely identity the true reasons for Large buying trading days over a two and a half years of accumulation.
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_8k.htm
http://www.firstwordmedtech.com/node/942328
http://www.srlworld.com/wellness/content/160/niche-wellness-test.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111964442
Feb 4, 2013 0.00 0.00 0.00 0.00 126,054,600 0.00
Feb 1, 2013 0.00 0.00 0.00 0.00 389,462,900 0.00
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=330
Radient is being restructured by a reverse merger. The majority of the stock is owned by institutional investors and Provista Diagnostics Angel investors. Someone mentioned that Radient was BROKE and should have gone bankrupt in June 2011 when indeed Radient was not in a bankrupt situation and to this day has never been. In Late September 2011, Radient was able to pay Alpha Capital the major 2011 lender 4.581,923 for the 4,559,842 million dollars to settle the 10.9 million owed to the :2011 lenders. The cash payment included 22,000 dollars of interest for one month after the settlement. The notes payable is reflected in the balance sheet from the last 10-K ending December 31, 2011.The remaining 6.0 million was converted into Radient stock by all of the 2011 lenders. The conversion took place after May 21, 2012 at .001 per share.
On May 21, 2012 Alpha and Whalehaven filed their SC 13 G's. In the settlement agreement the 2011 lenders were able to convert at .0001 per share.. The conversions started on May 25, 2012, according to the settlement before the 1/25 reverse split, Alpha was given 11,886,000 shares with protection, giving them 295 million shares. Whalehaven was given 9,114,000 shares which gives them after the reverse split, 127,850 million shares. In the agreement the 2011 collectively could not own more than 9.99 percent of the outstanding Radient stock..The 2011 at this time own 9.99 per cent of the RXPC stock and still holding. There is no way they would have converted at .001 and sold at .0001..That would give them less than 42,000 dollars...
The pps of the stock was at .02 before the conversions took place. The SC 13G's were filed on May 21, 2012..The conversions at .001 took place on May 25, 2012.
Jun 1, 2012 0.00 0.00 0.00 0.00 378,592,700 0.00
May 31, 2012 0.00 0.00 0.00 0.00 263,543,400 0.00
May 30, 2012 0.00 0.00 0.00 0.00 77,692,000 0.00
May 29, 2012 0.00 0.00 0.00 0.00 251,389,600 0.00
May 28, 2012 0.00 0.00 0.00 0.00 0 0.00
May 25, 2012 0.00 0.00 0.00 0.00 207,965,300 0.00
May 24, 2012 0.00 0.00 0.00 0.00 46,605,000 0.00
May 23, 2012 0.01 0.01 0.00 0.00 14,010,300 0.00
May 22, 2012 0.01 0.01 0.01 0.01 9,183,400 0.01
May 21, 2012 0.02 0.02 0.01 0.01 11,104,400 0.01
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528
Notes payable paid off in 2011.. Page 49 of the 10-K
4,581,923
http://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm
Under the terms of the Final Settlement Agreement, we issued our 8% convertible promissory notes in the principal amount of $4,559,842.41 to Alpha Capital and $3,496,415.91 to Whalehaven (the “Notes”). We are obligated retire the Notes in monthly installments, commencing January 31, 2012, by the payment in cash or (at our sole option) by delivery shares of our common stock in an amount equal to 6.25% of the principal amount of each Note, plus accrued interest. In the event we elect to make installment payments in common stock, we will be obligated to make monthly delivery of shares of common stock that are not subject to any restrictions on resale under Rule 144 under the Securities Act (“Non-Restricted Shares”) valued at 80% of the three lowest volume weighted average closing prices of our common stock over the 20 trading days immediately prior to each installment payment date. It is our present intention to amortize the Notes with our common stock, although we may elect to pay one or more such installments in cash. ,
The Notes permit the Plaintiffs to convert the Notes into our common stock, although the Final Settlement Agreement and the Notes contain “blocker” provisions designed to prevent the Plaintiffs from becoming “beneficial owners” (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act “) of more than 9.99% of our outstanding common stock, the Plaintiffs
We agreed to reserve an aggregate of 175.0 million shares of authorized and previously unissued Common Stock for potential issuance to the Plaintiffs for issuance upon their conversion of the Notes. We further agreed to keep a sufficient number of shares of Common Stock for purposes of enabling issuing all of the Settlement Shares pursuant to the Final Settlement Agreement and the Notes.
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm
This Final Settlement Agreement (the “Final Agreement”) is dated this 25th day of August 2011, to be effective as of August 19, 2011 (the “Effective Date”), is being entered into among Radient Pharmaceuticals Corporation (“RPC” or the “Company”), Whalehaven Capital Fund, Ltd. (“Whalehaven”) and Alpha Capital Anstalt (“Alpha Capital,” and together with Whalehaven, the “Plaintiffs” or the “Holder(s)”). The Company and the Holders are hereinafter sometimes collectively referred to as the “Parties.”
§ “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
“Converted Alpha Capital Notes” means notes aggregating $1,616,380.92 that were converted by Alpha Capital as part of the Initial Share Conversions into an aggregate of 11,886,000 Settlement Shares.
Converted Whalehaven Notes” means notes aggregating $1,239,415.76 that were converted by Whalehaven as part of the Initial Share Conversions into an aggregate of 9,114,000 Settlement Shares.
“Non-Restricted Shares” means shares of RPC Common Stock that are freely tradable, delivered without any restrictive legend and immediately resellable upon receipt by the Holder thereof pursuant to Rule 144(b)(1)(i) under the Securities Act of 1933, as amended, after November 2, 2011 without any additional holding period, volume limitations or manner of sale restrictions.
“Settlement Amount” shall mean the aggregate sum of $10,912,055 payable by the Company to the Plaintiffs under the Settlement Agreement and this Final Agreement, as to Alpha Capital in the amount of $6,176,223.13 and as to Whalehaven in the amount of $4,735,831.87.
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm
CONVERTIBLE PROMISSORY NOTE
FOR VALUE RECEIVED, RADIENT PHARMACEUTICALS CORPORATION, a Delaware corporation (hereinafter called “Debtor”), hereby promises to pay to the order of ALPHA CAPITAL ANSTALT (the “Holder”), with an address at Pradafant 7, 9490 Furstentums, Vaduz, Lichtenstein, Fax: 011-42-32323196, without demand, the sum of Four Million Five Hundred Fifty Nine Thousand Eight Hundred Forty Two Dollars Forty One Cents ($4,559,842.41) (“Principal Amount”), with interest accruing thereon, on April 15, 2013 (the “Maturity Date”), if not sooner paid or modified as permitted herein.
This Convertible Promissory Note (the “Note”) has been entered into pursuant to the terms of a Final Settlement Agreement by and among the Debtor, the Holder and another holder (the “Other Holder”) of a convertible promissory note (the “Other Note”), dated of even date herewith (the “Final Settlement Agreement”), for an aggregate Principal Amount of $8,056,258.32. Unless otherwise separately defined herein, each capitalized term used in this Note shall have the same meaning as set forth in the Final Settlement Agreement. The following terms shall apply to this Note:
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm
Alpha Capital Anstalt
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
6,496,317 shares of Common Stock
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x
The aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
http://www.sec.gov/Archives/edgar/data/838879/000121390012002926/sc13g052112alpha_radient.htm
Whalehaven Capital Fund Limited
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
6,496,317 shares of Common Stock
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x
The aggregate amount in Row 9 represents the maximum amount of shares that Whalehaven Capital Fund Limited can beneficially control under a contractually stipulated 9.99% ownership restriction.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm
We have concluded from the planned merger between Radient and Provista Diagnostics according to the LOI of 2010 and our completed analysis that Provista Diagnostics will either merge with Radient or reverse triangular merge Global Cancer Diagnostics with Radient.
The agreement between AMDL Diagnostics and Uni-Pharma and the agreement between Radient and Global Cancer Diagnostics were set up on a temporary basis and conveniently terminated after the last patent expired. Radient and Provista Diagnostics still have an exclusive 5 year agreement in force and Radient and Uni-Pharma are also in an exclusive and existing five year agreement. Those two agreements superseded the two previously terminated agreements. The Lung Cancer Test a/k/a LC Sentinel is still owned by Radient and Provista Diagnostics and included in their 5 year exclusive and collaborated agreement from November 2010 to research, develop, and commercialize cancer tests including the Lung Cancer Test. William Gartner sold his lung cancer and breast cancer to Provista Diagnostics in 2011.
The 4.5 billion RXPC shares outstanding are held by Institutional investors who had converted their debt for equity, and Angel investors who we believe are associated with Provista Diagnostics. After the announcement of revocation and insolvency, RXPC shares were accumulated and not sold. During the 2012 to July 3, 2014 period of trading,the creeping take over groups quietly took all the shares that Radient released slowly and in a timely manner to the public. If "ebabies" retailers etc that some are calling them were buying,they would have been the first to sell shares. As you can see from the lack of interest on this board before 2012 and after 2013...Enjoy our deductive logic approach to our premisses....
"Radient Is Being Restructured By A Planned Reverse Merger."
If:Radient wants and needs to be restructured by a merger and not by bankruptcy.
Then:Provista Diagnostics wants to go public
Therefore:Provista Diagnostics will merge according to the planned merger LOI of 2010 and the planned restructuring of Radient
*Uni-Pharma-Radient Dx Current Agreements and Past Agreement
http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2457187542.html
http://contractservices.pharmaceutical-business-review.com/news/radient-expands-distribution-agreement-with-unipharma-221211
http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm
*Radient Dx and Provista-Global Cancer Dx Current Agreements
http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_ex10-1.htm
*Radient Dx and Provista DX /Global Cancer DX Lung Cancer Test
http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001
http://www.bizjournals.com/phoenix/print-edition/2011/12/30/provista-to-go-public-with-breast.html
http://www.biocentury.com/products/lc_sentinel
*Over 38 Million Dollars Lender Debt Converted to Stock
http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112765409
http://seekingalpha.com/instablog/424698-m-e-garza/177461-regarding-latest-8k-filing-by-radient-pharmaceuticals-rpc
*All Accounts Payable Paid in Full By GCDx and Uni-Pharma Royalties/ License Agreements,Onko-Sure Sales in India,Taiwan,Korea,etc.and Attorney Debt to Equity Agreement
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112733314
*SRL Limited and Metropolis Healthcare Currently Selling Onko-Sure/Cancer 8 Throughout India
http://www.west-info.eu/it/analisi-del-sangue-13-tipi-tumore-cancro/2012-02-onkosure-fibrin-fdp-in-cancer-mm-2/
http://www.srlworld.com/wellness/content/160/niche-wellness-test.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111964442
http://www.metropolisindia.com/patients/cancer-eight
*Institutional Shareholders
http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html
http://www.sec.gov/Archives/edgar/data/838879/000121390012000035/0001213900-12-000035-index.htm
http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7538329
http://msnmoney.brand.edgar-online.com/DisplayFilingInfo.aspx?TabIndex=2&FilingID=7717117&type=html&companyid=4985&ppu=%2fDefault.aspx%3fticker%3drpc
http://www.sec.gov/Archives/edgar/data/838879/000136456011000007/stgeo_sc13g.htm
http://www.sec.gov/Archives/edgar/data/838879/000101968711002819/bristol_13ga-082411.htm
http://www.sec.gov/Archives/edgar/data/838879/000121390011003768/sc13g0711a1whale_radient.htm
http://www.sec.gov/Archives/edgar/data/838879/000121390011003763/sc13g0711a1alpha_radient.htm
http://www.sec.gov/Archives/edgar/data/838879/000090266411001142/p11-1347sc13g.htm
http://www.sec.gov/Archives/edgar/data/838879/000101968712000550/bristolradient_13ga2.htm
http://www.sec.gov/Archives/edgar/data/838879/000119312512059770/d301526dsc13ga.htm
http://www.sec.gov/Archives/edgar/data/838879/000090266412000289/p12-0319sc13ga.htm
Conclusion:
http://provistadx.com/
http://globalcancerdx.com/
http://azbio.tv/video/76134461f30e472d8f08be36f73bc095
http://seekingalpha.com/instablog/8702411-underdawg/2186492-the-many-veils-of-radient-pharmaceuticals-onko-sure-drminus-70
The link below will guide you to the complete analysis to our premisses.
"Radient Restructured By A Planned Reverse Merger"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714
Radient Is Being Restructured by A Reverse Merger
Part 1 April 20, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006
Part 2 April 21, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694
Part 3 April 22, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321
Part 4 April 23, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648
Part 5 April 24, 2015 Rebuttals
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841
Part 6 April 25, 2015 Rebuttals
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753
Conclusion: April 26, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999
Uni-Pharma Part 1 April 27, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285
Uni-Pharma Part 2 April 28, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567
Uni-Pharma Part 3 - Global Cancer Diagnostics Part 1
April 29, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113192928
GCDX and Uni-Pharma April 30, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113228108
Uni-Pharma Conlusion May 1, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113264286
May 2, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113295899
May 3, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714
May 4, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113319076
May 5, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113362336
All Roads Lead To Scottsdale, Arizona and Taipei,Taiwan Uni-Pharma Partnering with Global Cancer Diagnostics to Manufacture and Distribute Onko-Sure Overseas.
We will show how the Lenders converted and accumulated their limitation of 25 per cent of the RXPC outstanding shares along with the Provista/GCDX Angel investors 65 per cent of the outstanding and the 10 per cent of a few longs. Radient placed 4,509,000,000 shares into the float and the 491 million are for the Attorney firm that will be able to convert $300,000 of debt for around a holding of 34 million shares. The remaining shares will be for Mac, Akio,etc..The 1.8 million dollars of share based funds...Mac and Akio aren't going anywhere. Tomorrow we will break down the 25 per cent owned by the 2011 lenders 9.99 per cent,collectively, John Fife and St. George, 10 per cent, Capital Inventures 4.99 per cent. etc... Stay tuned
Gold Seeker Stated:
"Radient was insolvent in December 2012."
"That is when they disclosed that they owed $900,000 for operational costs (vendors, suppliers, leases) and had no way to pay. That is the definition of "insolvent."
Even if UNI still paid Radient the $200,000 per year royalty fee after the last patent expired, it would not have saved Radient from death.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113268667
Gold, You stated that Radient was insolvent in December 2012. When we saw that post, we knew that it couldn't be true..We did give you the benefit of the doubt and did some research. We checked all the 8-K's for the year 2012 and could not find the disclosure you stated or any language about "Radient being insolvent. We thought maybe you were referring to 2011 as well, but did not find it there, as well.
Here is what we found in 2012..
From an operational perspective, we continue to sell and ship Onko-Sure test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, the Company continues to maintain its operations in Tustin, relying on selective former employees that continue to work as consultants to the Company. We are also engaged in business discussions with other companies seeking to license Onko-Sure for various international territories. These licensing agreements, if completed, are anticipated to provide the Company with the funds necessary to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. There can be no guarantee that any new licensing transactions will be completed.
As of October 3, 2012, we had 3,235,210,154 shares of common stock issued and outstanding.
http://www.sec.gov/Archives/edgar/data/838879/000114420412054967/v325211_8ka.htm
http://www.sec.gov/cgi-bin/browse-edgar?company=Radient+Pharmaceuticals&owner=exclude&action=getcompany
This is the first 8-K in 2013 and the company is still selling Onko-Sure in territories specified within the 8-K..Still no mention of insolvency.
From an operational perspective, with appropriate capital, we can continue to sell and ship Onko-Sure® test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, we continue to maintain our offices and FDA approved manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. We are also engaged in business discussions with other companies seeking to license or purchase Onko-Sure for various domestic and international territories, although we have not entered into any formal agreements at this time. We are hopeful that if we can complete a sufficient number of these licensing and sales agreements, we will have enough capital to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. These agreements may also allow us to restructure or convert to equity our existing notes payable in order to significantly reduce or eliminate a majority of the liabilities on our balance sheet. There can be no guarantee that any new licensing, purchase or restructuring transactions will be completed or that they will provide sufficient capital to carry out our plans.
As of June 10th 2013, we had approximately 4,508,746,417 shares of common stock issued and outstanding.
http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113_radientpharm.htm
This is the only SEC filing we found stating that radient was insolvent. This is from May 6, 2013. Radient was NOT insolvent in December 2012 as you claim. We knew this wasn't true because Radient entered into an agreement with Global Cancer Diagnostics in October 2012 and was receiving licensing fees and royalty fees. In June 2013 AMDL Diagnostics a wholly owned subsidiary entered into an agreement with Uni-Pharma and received royalties as you stated in your post, except it was $100,000 and not $200,000 as you stated. The monies from Uni-Pharma were being collected by AMDL Diagnostics Inc. and were used to pay down the Radient debt. The monies from the India Government program and SRL Diagnostics and Metropolis are also being collected by AMDL.
Despite significant financial hardship, the Company continues to maintain its offices and manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. The Company is currently insolvent and the new Board of Directors and the new senior management of the Company have been appointed to attempt to restructure the Company. There can be no guarantee that any new business or restructuring transactions will be completed or that they will provide sufficient capital to carry out the Company's business.
On April 15, 2014, the Company executed an Offer of Settlement with the Securities and Exchange Commission (“Commission”) pursuant to Section 12(j) of the Securities Exchange Act of 1934, revoking the registration of the Company’s securities.
http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm
Gold Seeker also Stated:
"Radient revoked share registration to hide revenues?"
Instead of filing financials, Radient revoked share registration, because filing financials would reveal revenues that Radient wants to hide?
Radient said "we are insolvent" in an SEC filing when in truth they were making $$$ millions selling onko-sure in India?
If true, RXPC shareholders think this is good?"
Fascinating.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113368735
Gold, What we referring to is that Radient didn't file their 2012, 2013 and 2014 annual reports up to March 1, 2014.Radient became insolvent on March 1, 2014 when it became a Void Delaware Corporation.AMDL Diagnostics Inc has all the assets in their corporation along with the agreements. They are also paying down the debt. The Radient Corporation is insolvent but AMDL Diagnostics Inc. is still operation as the company has stated in their PR;s and SEC Filings since 2009 when the Corporation was formed.. The President of AMDL Diagnostics Inc. is Mac and the Secretary is Akio..They are also the officers of Radient. According to the May 6, 2013 8-K they did not resign as officers of radient. Mac is still the President and Akio is the Secretary..Here is the proof..SEC Filings are Facts you understand..Also you mentioned in a post that Mac couldn't be found.Mac is not hiding, he can be found in the AMDL Dianostics and the Radient Corporation as the President of both Corporations.
On April 30, 2014, the Board of Directors of the Company including Mr. Douglas C. MacLellan and Mr. Michael Christiansen appointed the following persons to the Company's Board: Mr. Jim Green, Mr. Darren Brown, Mr. Bill White and Mr. Dennis Charter. Additionally, the following persons will be appointed to the following positions:
Immediately following these appointments, Mr. MacLellan resigned as Chairman and CEO and Mr. Christiansen resigned as the Company's only other board member. Separately, Mr. Akio Ariura the Company's previous CFO and COO, resigned from both positions on April 28, 2014. None of these directors or officers resigned as a result of a disagreement with the Company.
http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm
Here is the SEC 8-K showing Mac as President and Akio as Secretary..Interesting they performed a Power of attorney in case one passed away..It was done on July 9, 2012 Four days prior to the Global Cancer Diagnostics agreement..
Signature Title Date
/s/ Douglas C. MacLellan President, Chief Executive Officer, and Director June 29, 2012
DOUGLAS C. MACLELLAN (Principal Executive Officer)
/s/ Akio Ariura Chief Operating Officer, Chief Financial Officer June 29, 2012
AKIO ARIURA and Secretary (Principal Financial Officer and Principal Accounting Officer)
/s/ Michael Boswell Director June 29, 2012
MICHAEL BOSWELL
Filing Date
2012-07-09
http://www.sec.gov/Archives/edgar/data/838879/000114420412038691/0001144204-12-038691-index.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420412037457/v317455_10ka.htm
The Power of attorney was signed on June 29, 2012 and posted on July 9, 2012..This is when Global Cancer Diagnostics and provista Diagnostics and the Angel Investors began their Creeping takeover of 65 per cent of the RXPC shares. Check out the volume the day before the Power of Attorney was signed and the day after the 10-K was filed. The Agreement between Radient and GCDX wasn't signed until July 13, 2012 and the 8-K was released on July 17, 2012... No retail or what you call"ebabies" even touched the stock.. This is because their weren't no "ebabies" buying the stock over the 2 year period, only Provista Angel Investors, Lenders converting, and a few investors including Dc and Guardianagel
Jul 18, 2012 0.00 0.00 0.00 0.00 28,268,400 0.00
Jul 17, 2012 0.00 0.00 0.00 0.00 22,938,000 0.00
Jul 16, 2012 0.00 0.00 0.00 0.00 36,264,300 0.00..
Jul 13, 2012 0.00 0.00 0.00 0.00 25,656,000 0.00
Jul 12, 2012 0.00 0.00 0.00 0.00 32,886,000 0.00
Jul 11, 2012 0.00 0.00 0.00 0.00 94,461,400 0.00
Jul 10, 2012 0.00 0.00 0.00 0.00 524,879,000 0.00
Jul 9, 2012 0.00 0.00 0.00 0.00 30,715,900 0.00
Jul 6, 2012 0.00 0.00 0.00 0.00 8,430,000 0.00
Jul 5, 2012 0.00 0.00 0.00 0.00 18,487,000 0.00
Jul 4, 2012 0.00 0.00 0.00 0.00 0 0.00
Jul 3, 2012 0.00 0.00 0.00 0.00 23,972,900 0.00
Jul 2, 2012 0.00 0.00 0.00 0.00 166,400,100 0.00
Jun 29, 2012 0.00 0.00 0.00 0.00 64,732,200 0.00
Jun 28, 2012 0.00 0.00 0.00 0.00 182,674,700 0.00
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
Mac and Akio will have the power to re-instate Radient Pharmaceuticals..Here is the Delaware Corporation Law.
may at any time procure an extension, restoration, renewal or revival of its charter, together with all the rights, franchises, privileges and immunities and subject to all of its duties, debts, and liabilities which had been secured or imposed by its original charter and all amendments thereto by filing with the Secretary of State a certificate of its last acting president and secretary or treasurer, or other officers to be elected as hereinafter provided, duly sworn or affirmed to by such officers before any person authorized by the laws of this State to administer oaths or affirmations, which certificate shall set forth:
If the last president and secretary or treasurer or the officers performing the functions of said offices or any of them of any such corporation so desiring to renew or revive its charter should be dead at the time of such renewal or should refuse or neglect to act with respect thereto as provided in the first paragraph of this section, the directors of such corporation or the survivors of them,....
http://delcode.delaware.gov/sessionlaws/ga105/chp147.shtml
Here is the breakdown of the Lender conversions and the Provista/GCDX Angel investors and a few longs.
*The Lenders started converting..6 Trading days totaling 1.226 Billion shares of volume.
May 24, 2012-June 1, 2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528
(Lender conversions along with Angel investors...5 Trading days and 584 Million shares of volume.
June 13, 2012-June 25, 2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528
*Lender conversions and Angel Investors..619 million shares of volume in 2 trading days.
June 28,2012-July 2,2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
*Lender conversions and Angel investors..1.2 Billion shares of volume in 4 trading days.
September 20, 2012-October 1, 2012
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
The 2012 conversions and accumulation volume totaled 4 billion in 20 trading days. That is an accumulation of 2 Billion shares being held by Lenders, Angel investors, and a few long investors.
*Lenders conversions and Angel investors.
1.3 billion volume in 6 trading days.
February 1, 2013-March 28, 2013
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=330
*Lender conversions and angel investors.
622 million of volume in 3 days of trading.
April 4, 2013-April 26, 2013
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=264
*Lender conversions and angel investors.
760 million shares of volume in 4 trading days.
July 3, 2013-July 9, 2013
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=198
Total volume in 2013 was 2.7 billion shares in 13 trading days. 1.35 billion shares accumulated.
*Angel investors.
780 million in volume in 2 trading days.
February 24, 2014-February 25, 2014
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=66
*Angel investors.
756 million shares of volume in 4 trading days.
March 20,2014-March 27,2014
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=66
*Angel investors
745 million shares of volume in 2 days of trading.
May 6, 2014-May 7,2014
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=0
2014 total volume 2.28 billion shares in 2 trading days. accumulation and holding 1.14 billion shares.
Total 2012,2013,and 2014...9 billion total volume in 35 trading days and 4.5 billion shares held by Lenders, Angel investors, and Longs...The lenders holding 25 per cent, angel investors 65 per cent and the longs 10 percent...During the time of the accumulation, the lenders converted shares up to their limitations. Then when Radient released more shares into the float, the lenders would purchase shares.. This was done a number of times..We have saved our emails from the transfer agent with the outstanding share count and when they were released...4.5 billion shares accumulated in 35 days.
DCSPKA You said:
SRL Diagnostics India and AMDL Australia connection will be heating up now that AMDL Australia has chosen not to renew its corporate status. Lets see exactly what effect it will have on Radient/AMDL Diagnostics.
I am especially interested on the synergy between AMDL Australia & AMDL Diagnostics.
AMDL Diagnostics- come out, come out, where ever you are?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111001885
Here's Jonny...Look who is checking out Jonny...
Jonny Deez
Orange County, California Area
https://www.linkedin.com/pub/jonny-deez/75/469/933?trk=pub-pbmap
Srinivas Yadav
it at AMDL Australia
Kurnool, Andhra Pradesh, India Medical Devices
https://www.linkedin.com/pub/srinivas-yadav/53/417/230?trk=pub-pbmap
Ikrar Khan
CSE at AMDL Australia
Noida Area, India Medical Devices
https://www.linkedin.com/pub/ikrar-khan/36/632/5a4?trk=pub-pbmap
Aussie with no mention of Radient..Go figure...Just a temp..lol
Darren Brown
Director at Cancer Screen Technologies Ltd
Melbourne Area, Australia
Management Consulting
Current
OnlineCapital Consulting, Cancer Screen Technologies Ltd
Previous
AMDL Australia, Hudson & Young, eWealthBuild Consulting
https://au.linkedin.com/in/dbrown197
***************************************************************
We have added these links to the SRL and Metropolis section of web sites. As you can see the two largest Diagnostics companies in India are selling Onko-Sure..SRL Limited and Metropolis Healthcare., Our sources told us that Metropolis is using the brand name Cancer 8 because SRL is using Onko-Sure.The 10 Million dollar deal with the India Government that was delayed in 2011 has apparently come to fruition. Radient had not filed their 2012,2013,2014 for a reason. To act like a private company without having to show the revenues from the India deal. The Indian deal consummated in 2013. On February 1, 2013, SRL sent out the first hint of the 10 million deal. Some will call this "India hype" or marijuana hype, whatever name was convenient at the time to falsely identity the true reasons for Large buying trading days over a two and a half years of accumulation.
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=462
http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_8k.htm
http://www.firstwordmedtech.com/node/942328
http://www.srlworld.com/wellness/content/160/niche-wellness-test.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111964442
Feb 4, 2013 0.00 0.00 0.00 0.00 126,054,600 0.00
Feb 1, 2013 0.00 0.00 0.00 0.00 389,462,900 0.00
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=330
Radient is being restructured by a reverse merger. The majority of the stock is owned by institutional investors and Provista Diagnostics Angel investors. Someone mentioned that Radient was BROKE and should have gone bankrupt in June 2011 when indeed Radient was not in a bankrupt situation and to this day has never been. In Late September 2011, Radient was able to pay Alpha Capital the major 2011 lender 4.581,923 for the 4,559,842 million dollars to settle the 10.9 million owed to the :2011 lenders. The cash payment included 22,000 dollars of interest for one month after the settlement. The notes payable is reflected in the balance sheet from the last 10-K ending December 31, 2011.The remaining 6.0 million was converted into Radient stock by all of the 2011 lenders. The conversion took place after May 21, 2012 at .001 per share.
On May 21, 2012 Alpha and Whalehaven filed their SC 13 G's. In the settlement agreement the 2011 lenders were able to convert at .0001 per share.. The conversions started on May 25, 2012, according to the settlement before the 1/25 reverse split, Alpha was given 11,886,000 shares with protection, giving them 295 million shares. Whalehaven was given 9,114,000 shares which gives them after the reverse split, 127,850 million shares. In the agreement the 2011 collectively could not own more than 9.99 percent of the outstanding Radient stock..The 2011 at this time own 9.99 per cent of the RXPC stock and still holding. There is no way they would have converted at .001 and sold at .0001..That would give them less than 42,000 dollars...
The pps of the stock was at .02 before the conversions took place. The SC 13G's were filed on May 21, 2012..The conversions at .001 took place on May 25, 2012.
Jun 1, 2012 0.00 0.00 0.00 0.00 378,592,700 0.00
May 31, 2012 0.00 0.00 0.00 0.00 263,543,400 0.00
May 30, 2012 0.00 0.00 0.00 0.00 77,692,000 0.00
May 29, 2012 0.00 0.00 0.00 0.00 251,389,600 0.00
May 28, 2012 0.00 0.00 0.00 0.00 0 0.00
May 25, 2012 0.00 0.00 0.00 0.00 207,965,300 0.00
May 24, 2012 0.00 0.00 0.00 0.00 46,605,000 0.00
May 23, 2012 0.01 0.01 0.00 0.00 14,010,300 0.00
May 22, 2012 0.01 0.01 0.01 0.01 9,183,400 0.01
May 21, 2012 0.02 0.02 0.01 0.01 11,104,400 0.01
http://finance.yahoo.com/q/hp?s=RXPC&a=1&b=1&c=1995&d=4&e=4&f=2015&g=d&z=66&y=528
Notes payable paid off in 2011.. Page 49 of the 10-K
4,581,923
http://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm
Under the terms of the Final Settlement Agreement, we issued our 8% convertible promissory notes in the principal amount of $4,559,842.41 to Alpha Capital and $3,496,415.91 to Whalehaven (the “Notes”). We are obligated retire the Notes in monthly installments, commencing January 31, 2012, by the payment in cash or (at our sole option) by delivery shares of our common stock in an amount equal to 6.25% of the principal amount of each Note, plus accrued interest. In the event we elect to make installment payments in common stock, we will be obligated to make monthly delivery of shares of common stock that are not subject to any restrictions on resale under Rule 144 under the Securities Act (“Non-Restricted Shares”) valued at 80% of the three lowest volume weighted average closing prices of our common stock over the 20 trading days immediately prior to each installment payment date. It is our present intention to amortize the Notes with our common stock, although we may elect to pay one or more such installments in cash. ,
The Notes permit the Plaintiffs to convert the Notes into our common stock, although the Final Settlement Agreement and the Notes contain “blocker” provisions designed to prevent the Plaintiffs from becoming “beneficial owners” (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act “) of more than 9.99% of our outstanding common stock, the Plaintiffs
We agreed to reserve an aggregate of 175.0 million shares of authorized and previously unissued Common Stock for potential issuance to the Plaintiffs for issuance upon their conversion of the Notes. We further agreed to keep a sufficient number of shares of Common Stock for purposes of enabling issuing all of the Settlement Shares pursuant to the Final Settlement Agreement and the Notes.
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm
This Final Settlement Agreement (the “Final Agreement”) is dated this 25th day of August 2011, to be effective as of August 19, 2011 (the “Effective Date”), is being entered into among Radient Pharmaceuticals Corporation (“RPC” or the “Company”), Whalehaven Capital Fund, Ltd. (“Whalehaven”) and Alpha Capital Anstalt (“Alpha Capital,” and together with Whalehaven, the “Plaintiffs” or the “Holder(s)”). The Company and the Holders are hereinafter sometimes collectively referred to as the “Parties.”
§ “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
“Converted Alpha Capital Notes” means notes aggregating $1,616,380.92 that were converted by Alpha Capital as part of the Initial Share Conversions into an aggregate of 11,886,000 Settlement Shares.
Converted Whalehaven Notes” means notes aggregating $1,239,415.76 that were converted by Whalehaven as part of the Initial Share Conversions into an aggregate of 9,114,000 Settlement Shares.
“Non-Restricted Shares” means shares of RPC Common Stock that are freely tradable, delivered without any restrictive legend and immediately resellable upon receipt by the Holder thereof pursuant to Rule 144(b)(1)(i) under the Securities Act of 1933, as amended, after November 2, 2011 without any additional holding period, volume limitations or manner of sale restrictions.
“Settlement Amount” shall mean the aggregate sum of $10,912,055 payable by the Company to the Plaintiffs under the Settlement Agreement and this Final Agreement, as to Alpha Capital in the amount of $6,176,223.13 and as to Whalehaven in the amount of $4,735,831.87.
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm
CONVERTIBLE PROMISSORY NOTE
FOR VALUE RECEIVED, RADIENT PHARMACEUTICALS CORPORATION, a Delaware corporation (hereinafter called “Debtor”), hereby promises to pay to the order of ALPHA CAPITAL ANSTALT (the “Holder”), with an address at Pradafant 7, 9490 Furstentums, Vaduz, Lichtenstein, Fax: 011-42-32323196, without demand, the sum of Four Million Five Hundred Fifty Nine Thousand Eight Hundred Forty Two Dollars Forty One Cents ($4,559,842.41) (“Principal Amount”), with interest accruing thereon, on April 15, 2013 (the “Maturity Date”), if not sooner paid or modified as permitted herein.
This Convertible Promissory Note (the “Note”) has been entered into pursuant to the terms of a Final Settlement Agreement by and among the Debtor, the Holder and another holder (the “Other Holder”) of a convertible promissory note (the “Other Note”), dated of even date herewith (the “Final Settlement Agreement”), for an aggregate Principal Amount of $8,056,258.32. Unless otherwise separately defined herein, each capitalized term used in this Note shall have the same meaning as set forth in the Final Settlement Agreement. The following terms shall apply to this Note:
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm
Alpha Capital Anstalt
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
6,496,317 shares of Common Stock
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x
The aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
http://www.sec.gov/Archives/edgar/data/838879/000121390012002926/sc13g052112alpha_radient.htm
Whalehaven Capital Fund Limited
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
6,496,317 shares of Common Stock
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x
The aggregate amount in Row 9 represents the maximum amount of shares that Whalehaven Capital Fund Limited can beneficially control under a contractually stipulated 9.99% ownership restriction.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm
We have concluded from the planned merger between Radient and Provista Diagnostics according to the LOI of 2010 and our completed analysis that Provista Diagnostics will either merge with Radient or reverse triangular merge Global Cancer Diagnostics with Radient.
The agreement between AMDL Diagnostics and Uni-Pharma and the agreement between Radient and Global Cancer Diagnostics were set up on a temporary basis and conveniently terminated after the last patent expired. Radient and Provista Diagnostics still have an exclusive 5 year agreement in force and Radient and Uni-Pharma are also in an exclusive and existing five year agreement. Those two agreements superseded the two previously terminated agreements. The Lung Cancer Test a/k/a LC Sentinel is still owned by Radient and Provista Diagnostics and included in their 5 year exclusive and collaborated agreement from November 2010 to research, develop, and commercialize cancer tests including the Lung Cancer Test. William Gartner sold his lung cancer and breast cancer to Provista Diagnostics in 2011.
The 4.5 billion RXPC shares outstanding are held by Institutional investors who had converted their debt for equity, and Angel investors who we believe are associated with Provista Diagnostics. After the announcement of revocation and insolvency, RXPC shares were accumulated and not sold. During the 2012 to July 3, 2014 period of trading,the creeping take over groups quietly took all the shares that Radient released slowly and in a timely manner to the public. If "ebabies" retailers etc that some are calling them were buying,they would have been the first to sell shares. As you can see from the lack of interest on this board before 2012 and after 2013...Enjoy our deductive logic approach to our premisses....
"Radient Is Being Restructured By A Planned Reverse Merger."
If:Radient wants and needs to be restructured by a merger and not by bankruptcy.
Then:Provista Diagnostics wants to go public
Therefore:Provista Diagnostics will merge according to the planned merger LOI of 2010 and the planned restructuring of Radient
*Uni-Pharma-Radient Dx Current Agreements and Past Agreement
http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2457187542.html
http://contractservices.pharmaceutical-business-review.com/news/radient-expands-distribution-agreement-with-unipharma-221211
http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm
*Radient Dx and Provista-Global Cancer Dx Current Agreements
http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_ex10-1.htm
*Radient Dx and Provista DX /Global Cancer DX Lung Cancer Test
http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001
http://www.bizjournals.com/phoenix/print-edition/2011/12/30/provista-to-go-public-with-breast.html
http://www.biocentury.com/products/lc_sentinel
*Over 38 Million Dollars Lender Debt Converted to Stock
http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm
http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112765409
http://seekingalpha.com/instablog/424698-m-e-garza/177461-regarding-latest-8k-filing-by-radient-pharmaceuticals-rpc
*All Accounts Payable Paid in Full By GCDx and Uni-Pharma Royalties/ License Agreements,Onko-Sure Sales in India,Taiwan,Korea,etc.and Attorney Debt to Equity Agreement
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112733314
*SRL Limited and Metropolis Healthcare Currently Selling Onko-Sure/Cancer 8 Throughout India
http://www.west-info.eu/it/analisi-del-sangue-13-tipi-tumore-cancro/2012-02-onkosure-fibrin-fdp-in-cancer-mm-2/
http://www.srlworld.com/wellness/content/160/niche-wellness-test.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111964442
http://www.metropolisindia.com/patients/cancer-eight
*Institutional Shareholders
http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html
http://www.sec.gov/Archives/edgar/data/838879/000121390012000035/0001213900-12-000035-index.htm
http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7538329
http://msnmoney.brand.edgar-online.com/DisplayFilingInfo.aspx?TabIndex=2&FilingID=7717117&type=html&companyid=4985&ppu=%2fDefault.aspx%3fticker%3drpc
http://www.sec.gov/Archives/edgar/data/838879/000136456011000007/stgeo_sc13g.htm
http://www.sec.gov/Archives/edgar/data/838879/000101968711002819/bristol_13ga-082411.htm
http://www.sec.gov/Archives/edgar/data/838879/000121390011003768/sc13g0711a1whale_radient.htm
http://www.sec.gov/Archives/edgar/data/838879/000121390011003763/sc13g0711a1alpha_radient.htm
http://www.sec.gov/Archives/edgar/data/838879/000090266411001142/p11-1347sc13g.htm
http://www.sec.gov/Archives/edgar/data/838879/000101968712000550/bristolradient_13ga2.htm
http://www.sec.gov/Archives/edgar/data/838879/000119312512059770/d301526dsc13ga.htm
http://www.sec.gov/Archives/edgar/data/838879/000090266412000289/p12-0319sc13ga.htm
Conclusion:
http://provistadx.com/
http://globalcancerdx.com/
http://azbio.tv/video/76134461f30e472d8f08be36f73bc095
http://seekingalpha.com/instablog/8702411-underdawg/2186492-the-many-veils-of-radient-pharmaceuticals-onko-sure-drminus-70
The link below will guide you to the complete analysis to our premisses.
"Radient Restructured By A Planned Reverse Merger"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714
Radient Is Being Restructured by A Reverse Merger
Part 1 April 20, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006
Part 2 April 21, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694
Part 3 April 22, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321
Part 4 April 23, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648
Part 5 April 24, 2015 Rebuttals
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841
Part 6 April 25, 2015 Rebuttals
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753
Conclusion: April 26, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999
Uni-Pharma Part 1 April 27, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285
Uni-Pharma Part 2 April 28, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567
Uni-Pharma Part 3 - Global Cancer Diagnostics Part 1
April 29, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113192928
GCDX and Uni-Pharma April 30, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113228108
Uni-Pharma Conlusion May 1, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113264286
May 2, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113295899
May 3, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714
May 4, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113319076
May 5, 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113362336
All Roads Lead To Scottsdale, Arizona and Taipei,Taiwan Uni-Pharma Partnering with Global Cancer Diagnostics to Manufacture and Distribute Onko-Sure Overseas.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
